NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route
Cancer Cell International,
Abstract Background Esophageal cancer (EC) is a global canker notorious for causing high mortality due to its relentless…